In a nutshell This study examined if adding biological therapy rituximab (Rituxan) to chemotherapy improved treatment results for children with non-Hodgkin lymphoma. The results showed that rituximab improved patients’ chances of survival but also caused more side effects. Some background Treatment results for children with NHL have...
Read MoreIn a nutshell This study compared two chemotherapy combinations – R-DHAP and R-DHAOx – to see which caused less kidney damage in patients with non-Hodgkin lymphoma (NHL). The results showed that fewer patients receiving R-DHAOx developed poor kidney function than patients receiving R-DHAP. Some background Combinations of chemotherapy...
Read MoreIn a nutshell This study examined how common side effects of the heart, including heart failure, were among patients with non-Hodgkin lymphoma who received CHOP or R-CHOP chemotherapy. The results showed that only a minority developed side effects and that older patients and female patients were more likely to develop them. Some background Both...
Read MoreIn a nutshell This study examined the long-term survival of patients who received stem cell transplants (SCT) and compared them to the general population. The authors found that patients who received SCTs had almost the same chance of survival as the general population and identified factors that alter this chance. Some background Treatments such as...
Read MoreIn a nutshell This study examined the effects of granulocyte colony-stimulating factor (G-CSF) given as a preventative measure in patients with high- and medium-risk cancer receiving chemotherapy. The results showed that preventative G-CSF allowed more patients to complete chemotherapy treatment and lowered patients’ chances of developing secondary...
Read MoreIn a nutshell This study evaluated the outcomes of the R-BAC (rituximab, bendamustine, cytarabine) regimen for patients with relapsed or unresponsive mantle cell lymphoma (MCL). This study concluded that R-BAC was effective for these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL). After initial...
Read MoreIn a nutshell This study evaluated the safety and effectiveness of bendamustine-EAM (Be-EAM) chemotherapy for patients with mantle cell lymphoma (MCL) before a stem cell transplant. This study found that this regimen improved survival outcomes compared to standard regimens. Some background Stem cell transplants (SCT) remain the standard of care for...
Read MoreIn a nutshell This looked at the safety and effectiveness of copanlisib (Aliqopa) for B-cell lymphoma that returned after previous treatment. This study found that long-term copanlisib treatment was safe and effective. Some background Indolent (painless) B-cell lymphoma is a slow-growing blood cancer. B-cell lymphoma that comes back or...
Read MoreIn a nutshell This study evaluated the safety and effectiveness of high-dose cyclophosphamide (Cytoxan) for the treatment of relapsed or unresponsive non-Hodgkin’s lymphoma (NHL). This study concluded that high-dose cyclophosphamide was safe and effective for these patients. Some background Chemotherapy regimens remain a standard treatment...
Read MoreIn a nutshell This study evaluated the effectiveness of allogeneic stem cell transplants (allo-SCT) in elderly patients with non-Hodgkin’s lymphoma (NHL). This study found that allo-SCT has improved survival outcomes for these patients. Some background Allogeneic stem cell transplantation (allo-SCT) can be highly effective for patients with...
Read MoreIn a nutshell This study compared the effectiveness and safety of acalabrutinib (Calquence) to other targeted therapies for patients with mantle cell lymphoma (MCL). The authors found that acalabrutinib was just as safe and more effective for these patients. Some background MCL is a type of non-Hodgkin's lymphoma treated in...
Read MoreIn a nutshell This study evaluated the risk factors associated with delayed engraftment (DE) in patients who had stem cell transplantation (SCT). The authors found that patients receiving blood transfusions, those with low platelet levels, and those given low numbers of stem cells during SCT were more likely to experience DE. Some background...
Read More
